N. BILLERICA, Mass.--(BUSINESS WIRE)-- Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic medical imaging, today announced that the U.S. Food and Drug Administration (FDA) has accepted ...
“The label change implemented by FDA is reflective of both the extensive data on contrast agents and the well characterized and stable safety profile of DEFINITY, which has been used to perform more ...
BEDFORD, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight ...
Please provide your email address to receive an email when new articles are posted on . Lantheus Medical Imaging Inc. announced that the FDA has approved a label update that removes the ...
NORTH BILLERICA, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (LNTH) (the Company) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, ...
Although contrast agents have an essential role in non-invasive imaging techniques, potential side effects limit their use. For example, both low- and iso-osmolar iodinated contrast media used in ...
LOS ANGELES — Real-time myocardial contrast echocardiography (RTMCE) to detect coronary disease yields more abnormal studies and is more likely to detect multivessel coronary disease than regular ...
In a comparison of patient outcomes after two stress imaging approaches, stress real-time myocardial contrast echocardiography improved the detection of CAD during stress echocardiography over ...
Up to 20 percent of all resting echocardiography studies and up to 30 percent of those conducted in critical care patients can result in suboptimal echocardiograms. 3-6 A suboptimal image is one in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results